Psychiatric Times

12/24/2025

Earn CME credit before 2025 ends! Check out our latest CME here:

In this CME article, explore effective strategies for assessing and preventing su***de risk in patients with bipolar disorder, including interdisciplinary approaches and evidence-based interventions.

12/24/2025

As we reflect on the year, we’re grateful for the compassion and commitment of the mental health community. Wishing you comfort, connection, and well-being this holiday season. Happy holidays. ❄️💙

12/23/2025

Mirtazapine and duloxetine show significant efficacy in reducing negative symptoms of schizophrenia when used with antipsychotics.

Meta-analysis identifies 2 antidepressants that separate from placebo and other antidepressants in relieving negative symptoms of schizophrenia

12/22/2025

Athletes face psychiatric disorders at rates comparable to the general population, with treatment options limited by WADA restrictions. Explore how transcranial magnetic stimulation enhances athletic performance and mental health.

Explore how transcranial magnetic stimulation enhances athletic performance and mental health, offering innovative solutions for athletes facing psychological challenges.

12/19/2025

Analysis Insights: Learn how to critically analyze randomized controlled trials to ensure trustworthy results and improve clinical decision-making in mental health care.

Learn how to critically analyze randomized controlled trials to ensure trustworthy results and improve clinical decision-making in mental health care.

12/18/2025

Explore the transformative impact of lifestyle psychiatry on mental health, emphasizing exercise, nutrition, and connectedness for improved well-being in our latest Special Report. https://www.psychiatrictimes.com/view/continuing-conversations-in-lifestyle-psychiatry

12/18/2025

Learn more about the important aspects of therapeutic drug monitoring of clozapine. Join expert Jonathan M. Meyer, MD, DLFAPA as he reviews TDM’s evidence-based rationale, explores rapid testing technologies, and focused on improving patient outcomes.
Watch now: https://hubs.li/Q03YxdvX0

12/15/2025

The American Foundation for Su***de Prevention has launched Clinical Approach to Preventing Su***de: An Introduction (CAPS), a presentation that is designed to educate primary care and/or emergency health care professionals about their role in su***de prevention. The 90-minute presentation provides an overview of how to identify patients at risk for su***de, brief interventions, and treatment options.

Christine Yu Moutier shared her insights with us on this new program. Read more here:

AFSP's new CAPS program empowers health care professionals with essential skills to identify and support patients at risk for su***de effectively.

12/09/2025

🚨NDA Submission: has submitted an NDA to the FDA for extended-release injectable olanzapine for the treatment of schizophrenia in adults.

Teva Pharmaceuticals has submitted an NDA to the FDA for extended-release injectable olanzapine for the treatment of schizophrenia.

12/08/2025

Psychedelics for mental health disorders: According to new positive phase 2 data, Incannex Healthcare's PSX-001, a psilocybin-assisted psychotherapy treatment for generalized anxiety disorder, showed statistically significant and clinically meaningful improvements in patients with moderate to severe anxiety. We chatted with Lou Barbato, MD, the chief medical officer of Incannex, to learn more.

Psychiatric Times is the connection to Psychiatry and Mental Health, featuring clinical updates, expert views, and research news in multimedia formats.

12/04/2025

❄️ The December issue of Psychiatric Times is now live! This month, we take closer look at the IV lorazepam shortage and the concept of psychopathology.

Download the issue now and follow along as articles are shared throughout the month.https://cdn.sanity.io/files/0vv8moc6/psychtimes/380554b5a2e6ecc1bf177048b282b991f783cf9d.pdf